JP7850721B2 - Psmaおよびエフェクタ細胞抗原を標的とする腫瘍活性化抗体に関連する組成物ならびに方法 - Google Patents

Psmaおよびエフェクタ細胞抗原を標的とする腫瘍活性化抗体に関連する組成物ならびに方法

Info

Publication number
JP7850721B2
JP7850721B2 JP2023534888A JP2023534888A JP7850721B2 JP 7850721 B2 JP7850721 B2 JP 7850721B2 JP 2023534888 A JP2023534888 A JP 2023534888A JP 2023534888 A JP2023534888 A JP 2023534888A JP 7850721 B2 JP7850721 B2 JP 7850721B2
Authority
JP
Japan
Prior art keywords
polypeptide
seq
polypeptide complex
tumor
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023534888A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023552812A5 (cg-RX-API-DMAC7.html
JP2023552812A (ja
Inventor
キャンベル,デイビッド
アール. ディライモンド,トーマス
Original Assignee
ジャナックス セラピューティクス,インク.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジャナックス セラピューティクス,インク. filed Critical ジャナックス セラピューティクス,インク.
Publication of JP2023552812A publication Critical patent/JP2023552812A/ja
Publication of JP2023552812A5 publication Critical patent/JP2023552812A5/ja
Priority to JP2026002859A priority Critical patent/JP2026084109A/ja
Application granted granted Critical
Publication of JP7850721B2 publication Critical patent/JP7850721B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2023534888A 2020-12-09 2021-12-07 Psmaおよびエフェクタ細胞抗原を標的とする腫瘍活性化抗体に関連する組成物ならびに方法 Active JP7850721B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026002859A JP2026084109A (ja) 2020-12-09 2026-01-09 Psmaおよびエフェクタ細胞抗原を標的とする腫瘍活性化抗体に関連する組成物ならびに方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063123329P 2020-12-09 2020-12-09
US63/123,329 2020-12-09
US202163187699P 2021-05-12 2021-05-12
US63/187,699 2021-05-12
PCT/US2021/062249 WO2022125576A1 (en) 2020-12-09 2021-12-07 Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026002859A Division JP2026084109A (ja) 2020-12-09 2026-01-09 Psmaおよびエフェクタ細胞抗原を標的とする腫瘍活性化抗体に関連する組成物ならびに方法

Publications (3)

Publication Number Publication Date
JP2023552812A JP2023552812A (ja) 2023-12-19
JP2023552812A5 JP2023552812A5 (cg-RX-API-DMAC7.html) 2024-12-11
JP7850721B2 true JP7850721B2 (ja) 2026-04-23

Family

ID=81849994

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023534888A Active JP7850721B2 (ja) 2020-12-09 2021-12-07 Psmaおよびエフェクタ細胞抗原を標的とする腫瘍活性化抗体に関連する組成物ならびに方法
JP2026002859A Pending JP2026084109A (ja) 2020-12-09 2026-01-09 Psmaおよびエフェクタ細胞抗原を標的とする腫瘍活性化抗体に関連する組成物ならびに方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026002859A Pending JP2026084109A (ja) 2020-12-09 2026-01-09 Psmaおよびエフェクタ細胞抗原を標的とする腫瘍活性化抗体に関連する組成物ならびに方法

Country Status (9)

Country Link
US (4) US11555078B2 (cg-RX-API-DMAC7.html)
EP (1) EP4259193A4 (cg-RX-API-DMAC7.html)
JP (2) JP7850721B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230135575A (cg-RX-API-DMAC7.html)
AU (1) AU2021396172A1 (cg-RX-API-DMAC7.html)
CA (1) CA3201588A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023006817A (cg-RX-API-DMAC7.html)
TW (2) TW202617780A (cg-RX-API-DMAC7.html)
WO (1) WO2022125576A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230092863A (ko) 2020-06-11 2023-06-26 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
CN116981682A (zh) * 2020-12-08 2023-10-31 佳努克斯治疗公司 用于抗-cd3结合结构域的肽组合物和方法
EP4259193A4 (en) 2020-12-09 2025-01-15 Janux Therapeutics, Inc. Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens
MX2023013851A (es) 2021-05-24 2023-12-08 Provention Bio Inc Metodos para el tratamiento de diabetes tipo 1.
JP7855148B2 (ja) 2023-02-10 2026-05-07 アムニクス ファーマシューティカルズ, インコーポレイテッド 前立腺特異的膜抗原(psma)を標的とする組成物、並びにそれを作製及び使用するための方法
CN121843965A (zh) * 2023-07-14 2026-04-10 佳努克斯治疗公司 靶向psma和效应细胞抗原的肿瘤激活抗体相关的组合物和方法
TW202528349A (zh) * 2023-11-03 2025-07-16 美商詹努克斯治療有限公司 用於靶向psma及cd28之抗體及其用途
WO2026096559A1 (en) * 2024-11-01 2026-05-07 Janux Therapeutics, Inc. Antibodies for targeting psma and uses thereof
US20260226165A1 (en) * 2024-12-17 2026-08-06 Merck Sharp & Dohme Llc Compositions and methods related to tumor activated molecules targeting nectin-4 and effector cell antigens
WO2026156021A1 (en) 2025-01-16 2026-07-23 Merck Sharp & Dohme Llc Bispecific antibody constructs that bind alpp/alppl2 and cd3

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017184723A (ja) 2016-02-03 2017-10-12 アムゲン リサーチ (ミュンヘン) ゲーエムベーハーAMGEN Research(Munich)GmbH Psmaおよびcd3に対する二重特異性を有するt細胞エンゲージ抗体コンストラクト
JP2018520642A (ja) 2015-05-01 2018-08-02 ジェネンテック, インコーポレイテッド マスク抗cd3抗体及びその使用方法
JP2019514850A (ja) 2016-03-22 2019-06-06 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト プロテアーゼ活性化t細胞二重特異性分子
WO2019222278A1 (en) 2018-05-14 2019-11-21 Harpoon Therapeutics, Inc. Dual binding moiety
WO2019222283A1 (en) 2018-05-14 2019-11-21 Harpoon Therapeutics, Inc. Binding moiety for conditional activation of immunoglobulin molecules
JP2019535763A (ja) 2016-11-23 2019-12-12 ハープーン セラピューティクス,インク. 前立腺特異的膜抗原(psma)を標的とする三重特異性タンパク質と使用方法

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747654A (en) 1993-06-14 1998-05-05 The United States Of America As Represented By The Department Of Health And Human Services Recombinant disulfide-stabilized polypeptide fragments having binding specificity
US20010031264A1 (en) 1996-01-25 2001-10-18 Andrew Segal Vaccine compositions and methods of modulating immune responses
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US20040175756A1 (en) 2001-04-26 2004-09-09 Avidia Research Institute Methods for using combinatorial libraries of monomer domains
US20050215472A1 (en) 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
WO2003034903A2 (en) 2001-10-23 2003-05-01 Psma Development Company, L.L.C. Psma antibodies and protein multimers
AU2004242845B2 (en) 2003-05-31 2011-06-02 Amgen Research (Munich) Gmbh Human-anti-human CD3 binding molecules
JP2009540015A (ja) 2006-06-14 2009-11-19 イムクローン・リミテッド・ライアビリティ・カンパニー 抗egfr抗体の凍結乾燥製剤
WO2008119565A2 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific binding domain
WO2008119567A2 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific cd3-epsilon binding domain
JP5718640B2 (ja) 2007-08-21 2015-05-13 アムジエン・インコーポレーテツド ヒトc−fms抗原結合性タンパク質
KR101652125B1 (ko) 2007-09-26 2016-08-29 우드라이 파마 게엠베하 헤파린-결합 표피 성장 인자-유사 성장 인자 항원 결합 단백질
TW200944231A (en) 2007-11-30 2009-11-01 Glaxo Group Ltd Antigen-binding constructs
MX2011003502A (es) 2008-10-01 2011-09-01 Micromet Ag Anticuerpo de cadena sencilla biespecifica de psmaxcd3 especifico a traves de especies.
EP2352763B2 (en) 2008-10-01 2022-09-21 Amgen Research (Munich) GmbH Bispecific single chain antibodies with specificity for high molecular weight target antigens
EP3543256A1 (en) 2009-01-12 2019-09-25 Cytomx Therapeutics Inc. Modified antibody compositions, methods of making and using thereof
TWI653333B (zh) * 2010-04-01 2019-03-11 安進研究(慕尼黑)有限責任公司 跨物種專一性之PSMAxCD3雙專一性單鏈抗體
WO2011123830A2 (en) 2010-04-02 2011-10-06 Amunix Operating Inc. Alpha 1-antitrypsin compositions and methods of making and using same
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
JP6407726B2 (ja) 2012-03-01 2018-10-24 アムゲン リサーチ (ミュンヘン) ゲーエムベーハーAMGEN Research(Munich)GmbH 長寿命ポリペプチド結合分子
PE20150605A1 (es) 2012-04-27 2015-05-28 Cytomx Therapeutics Inc Anticuerpos activables que se unen al receptor del factor de crecimiento epidermico
WO2013192546A1 (en) 2012-06-22 2013-12-27 Cytomx Therapeutics, Inc. Activatable antibodies having non-binding steric moieties and mehtods of using the same
BR112015000798A2 (pt) * 2012-07-13 2017-06-27 Zymeworks Inc heterodímeros assimétricos biespecíficos compreendendo construtos anti-cd3
SMT201800335T1 (it) 2012-11-06 2018-09-13 Bayer Pharma AG Formulazione di attivatori bispecifici per linfociti t (bite)
US9562110B2 (en) 2012-11-21 2017-02-07 Wuhan Yzy Biopharma Co., Ltd. Bispecific antibody
US20160017058A1 (en) 2013-03-14 2016-01-21 The California Institute For Biomedical Research Bispecific antibodies and uses thereof
UY35484A (es) 2013-03-15 2014-10-31 Amgen Res Munich Gmbh Molécula de unión de cadena simple que comprenden ABP de extremo N
EP3628328B1 (en) 2014-01-31 2022-09-14 Cytomx Therapeutics Inc. Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof
CA2955947A1 (en) 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
ES2743809T3 (es) 2014-07-31 2020-02-20 Amgen Res Munich Gmbh Constructos de anticuerpo monocatenarios biespecificos específicos de especies cruzadas optimizados
EP3197916A2 (en) 2014-09-25 2017-08-02 Amgen Inc. Protease-activatable bispecific proteins
WO2016077505A2 (en) 2014-11-11 2016-05-19 Amunix Operating Inc. Targeted xten conjugate compositions and methods of making same
IL300408B2 (en) 2015-01-20 2025-11-01 Cytomx Therapeutics Inc Matrix metalloprotease-cleavable and serine protease cleavable substrates and methods of use thereof
TWI787796B (zh) 2015-05-04 2022-12-21 美商Cytomx生物製藥公司 抗cd71抗體類、可活化之抗cd71抗體類及使用彼等之方法
EP3297672B1 (en) 2015-05-21 2021-09-01 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
WO2017008844A1 (en) 2015-07-14 2017-01-19 Biontech Ag Peptide mimotopes of the cd3 t-cell co-receptor epsilon chain and uses thereof
JOP20160154B1 (ar) 2015-07-31 2021-08-17 Regeneron Pharma أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
AU2017229687A1 (en) 2016-03-08 2018-09-20 Takeda Pharmaceutical Company Limited Inducible binding proteins and methods of use
BR112018071307A2 (pt) 2016-04-18 2019-02-26 Celldex Therapeutics, Inc. anticorpos agonistas que ligam cd40 humana e usos dos mesmos
HRP20251020T1 (hr) 2016-05-20 2025-10-24 Harpoon Therapeutics, Inc. Proteini s jednolančanim varijabilnim fragmentom koji vežu cd3
KR102530742B1 (ko) 2016-05-20 2023-05-09 하푼 테라퓨틱스, 인크. 단일 도메인 혈청 알부민 결합 단백질
CN110072890B (zh) 2016-11-03 2022-11-29 百时美施贵宝公司 可活化的抗ctla-4抗体及其用途
AU2017364818C1 (en) 2016-11-28 2025-05-15 Chugai Seiyaku Kabushiki Kaisha Ligand-binding molecule having adjustable ligand binding activity
JP2020518240A (ja) 2017-01-17 2020-06-25 ザ テキサス エー アンド エム ユニバーシティー システム 標的細胞のエンドリソソーム区画へのカーゴ分子の送達の向上のためのエンドリソソーム標的化コンジュゲート
US10730954B2 (en) * 2017-05-12 2020-08-04 Harpoon Therapeutics, Inc. MSLN targeting trispecific proteins and methods of use
CN111356700A (zh) 2017-09-08 2020-06-30 马弗里克治疗公司 受约束的条件性活化的结合蛋白
CN111247171A (zh) 2017-10-14 2020-06-05 西托姆克斯治疗公司 抗体、可活化抗体、双特异性抗体和双特异性可活化抗体及其使用方法
US11673954B2 (en) 2017-11-17 2023-06-13 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against PD-L1
KR20260039804A (ko) * 2017-12-21 2026-03-20 아뮤닉스 파마슈티컬스, 인크. 유리 세그먼트 및 이것을 포함하는 결합 조성물
KR102834864B1 (ko) 2018-02-02 2025-07-16 온코씨4, 아이앤씨. 개선된 면역치료 효과를 갖지만 약화된 부작용을 갖는 돌연변이 항-ctla-4 항체
CN112005304A (zh) 2018-03-20 2020-11-27 西托姆克斯治疗公司 用于哺乳动物受试者中的可活化抗体种类的定量药理学建模的系统和方法
WO2019222282A1 (en) 2018-05-14 2019-11-21 Harpoon Therapeutics, Inc. Conditionally activated binding protein comprising a sterically occluded target binding domain
EP3833444A1 (en) 2018-08-09 2021-06-16 Maverick Therapeutics, Inc. Coexpression and purification method of conditionally activated binding proteins
EP3847196A4 (en) 2018-09-07 2023-01-04 ITabMed (HK) Limited BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
US20230132385A9 (en) 2018-09-20 2023-04-27 Tikcro Technologies Ltd. Antibodies specific to ctla-4 and uses thereof
CN113286812B (zh) 2018-09-27 2025-05-30 西里欧发展公司 掩蔽型细胞因子多肽
JP2022512124A (ja) 2018-12-06 2022-02-02 シートムエックス セラピューティクス,インコーポレイテッド マトリックスメタロプロテアーゼ切断可能なおよびセリンまたはシステインプロテアーゼ切断可能な基質ならびにそれらの使用方法
MX2021006930A (es) * 2018-12-11 2021-11-17 Q32 Bio Inc Construcciones de proteínas de fusión para enfermedades asociadas al complemento.
EP3911371A4 (en) * 2019-01-18 2023-04-26 University of Southern California METHODS AND COMPOSITIONS FOR IMPROVING THE SAFETY AND EFFICACY OF CELL THERAPY
JP2022524337A (ja) 2019-03-05 2022-05-02 武田薬品工業株式会社 腫瘍抗原を標的とするfc領域及び部分を含有する条件的に活性化された結合タンパク質
EP4592313A3 (en) 2019-03-05 2025-11-19 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins
CN113811546B (zh) * 2019-05-07 2025-03-11 免疫里森公司 前体三特异性抗体构建体及其使用方法
US20230220105A1 (en) 2019-06-06 2023-07-13 Janux Therapeutics, Inc. Tumor activated t cell engagers and methods of use thereof
WO2020264200A1 (en) 2019-06-26 2020-12-30 Amunix Pharmceuticals, Inc. Cd3 antigen binding fragments and compositions comprising same
AU2021326469C1 (en) 2020-08-11 2026-04-30 Janux Therapeutics, Inc. Cleavable linker compositions and methods
WO2022060878A1 (en) * 2020-09-16 2022-03-24 Amgen Inc. Methods for treating prostate cancer
CA3196055A1 (en) 2020-09-28 2022-03-31 Navrogen, Inc. Composition and use of alternatively formatted anti-mesothelin antibodies for the treatment of cancer
US20240043565A1 (en) 2020-10-15 2024-02-08 Janux Therapeutics, Inc. Antibodies targeting psma and cd3 and uses thereof
US20240228656A1 (en) * 2020-11-06 2024-07-11 Harpoon Therapeutics, Inc. Epcam targeting trispecific protein for treatment of cancer
WO2022125566A1 (en) 2020-12-08 2022-06-16 Janux Therapeutics, Inc. Half-life extending compositions and methods
CN116981682A (zh) 2020-12-08 2023-10-31 佳努克斯治疗公司 用于抗-cd3结合结构域的肽组合物和方法
EP4259193A4 (en) 2020-12-09 2025-01-15 Janux Therapeutics, Inc. Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens
KR20250024874A (ko) 2022-04-04 2025-02-19 재눅스 테라퓨틱스 인크. Psma 및 이펙터 세포 항원을 표적으로 하는 종양 활성화 항체와 관련된 조성물 및 방법
US20240059790A1 (en) 2022-04-04 2024-02-22 Janux Therapeutics, Inc. Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018520642A (ja) 2015-05-01 2018-08-02 ジェネンテック, インコーポレイテッド マスク抗cd3抗体及びその使用方法
JP2017184723A (ja) 2016-02-03 2017-10-12 アムゲン リサーチ (ミュンヘン) ゲーエムベーハーAMGEN Research(Munich)GmbH Psmaおよびcd3に対する二重特異性を有するt細胞エンゲージ抗体コンストラクト
JP2019514850A (ja) 2016-03-22 2019-06-06 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト プロテアーゼ活性化t細胞二重特異性分子
JP2019535763A (ja) 2016-11-23 2019-12-12 ハープーン セラピューティクス,インク. 前立腺特異的膜抗原(psma)を標的とする三重特異性タンパク質と使用方法
WO2019222278A1 (en) 2018-05-14 2019-11-21 Harpoon Therapeutics, Inc. Dual binding moiety
WO2019222283A1 (en) 2018-05-14 2019-11-21 Harpoon Therapeutics, Inc. Binding moiety for conditional activation of immunoglobulin molecules

Also Published As

Publication number Publication date
CA3201588A1 (en) 2022-06-16
EP4259193A1 (en) 2023-10-18
TW202617780A (zh) 2026-05-01
US20220177600A1 (en) 2022-06-09
JP2023552812A (ja) 2023-12-19
TW202237654A (zh) 2022-10-01
EP4259193A4 (en) 2025-01-15
TWI900703B (zh) 2025-10-11
JP2026084109A (ja) 2026-05-20
AU2021396172A1 (en) 2023-07-06
US20260001963A1 (en) 2026-01-01
US20230348618A1 (en) 2023-11-02
US12617865B2 (en) 2026-05-05
MX2023006817A (es) 2023-08-14
WO2022125576A1 (en) 2022-06-16
US11555078B2 (en) 2023-01-17
KR20230135575A (ko) 2023-09-25
US20260217858A1 (en) 2026-07-30

Similar Documents

Publication Publication Date Title
JP2026084109A (ja) Psmaおよびエフェクタ細胞抗原を標的とする腫瘍活性化抗体に関連する組成物ならびに方法
JP7681681B2 (ja) 切断可能リンカー組成物および方法
US20260014267A1 (en) Compositions and methods related to tumor activated antibodies targeting egfr and effector cell antigens
US20240034806A1 (en) Compositions and methods related to tumor activated antibodies targeting trop2 and effector cell antigens
JP2023552462A (ja) 半減期延長組成物および方法
CN116981682A (zh) 用于抗-cd3结合结构域的肽组合物和方法
TW202400659A (zh) 經腫瘤活化之靶向cd28及pd-l1之多特異性抗體及其使用方法
US20240254241A1 (en) Antibodies targeting egfr and cd3 and uses thereof
US20240043565A1 (en) Antibodies targeting psma and cd3 and uses thereof
TW202528349A (zh) 用於靶向psma及cd28之抗體及其用途
CN117042792A (zh) 涉及靶向psma和效应细胞抗原的肿瘤活化抗体的组合物和方法
HK40101255A (en) Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens
CN117042801A (zh) 涉及靶向trop2和效应细胞抗原的肿瘤活化抗体的组合物和方法
HK40109153A (en) Compositions and methods related to tumor activated antibodies targeting egfr and effector cell antigens
TW202535942A (zh) 用於靶向cd28之抗體及其用途
CN116997573A (zh) 靶向psma和cd3的抗体及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231006

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241203

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241203

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20241206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250210

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250430

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250703

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20250709

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20250711

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250808

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250909

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260413

R150 Certificate of patent or registration of utility model

Ref document number: 7850721

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150